Staff Profile: Jing Chen

Jing Chen
Jing Chen, Ph.D.

Scientific Review Officer

Office of Grants Management and Scientific Review

National Center for Advancing Translational Sciences

National Institutes of Health

Email Jing Chen

Biography

Jing Chen is a scientific review officer in NCATS’ Office of Grants Management and Scientific Review, where she works in partnership with the scientific community to ensure that applications submitted to NCATS receive fair, independent, expert and timely scientific reviews — free from inappropriate influences — to help ensure that NCATS funds the most promising research. Prior to joining NCATS, she was a staff scientist at the National Cancer Institute (NCI) and National Eye Institute (NEI). Chen was involved in several clinical trials at NCI and NEI, and her research was focused primarily on immunotherapy, drug development and lymphoid malignancies. Her research has led to many Phase I/II clinical trials, one investigational new drug application to the U.S. Food and Drug Administration, and one patent application.

Chen received her Bachelor of Science in biochemistry from Sichuan University in Chengdu, Sichuan, China, and her doctorate in molecular biology from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Science, China. She received her postdoctoral training in the Department of Cell Biology at NCI and was awarded a research fellow position in the Jerome H. Holland Laboratory at the American Red Cross.

Research Topics

Chen’s research interests include basic and clinical immunology, focusing on the regulation of the human immune response and how its dysregulation can lead to autoimmune, immunodeficiency and malignant disorders. Insights gained in the fundamental research are applied to the development of new approaches to patient treatments.

Selected Publications

  1. Cytokine Receptor Signaling Is Required for the Survival of ALK- Anaplastic Large Cell Lymphoma, Even in the Presence of JAK1/STAT3 Mutations
  2. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy
  3. Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients with Cancer
  4. Insulin-Dependent Diabetes Induced by Pancreatic Beta Cell Expression of IL-15 and IL-15Rα
  5. Markedly Additive Antitumor Activity with the Combination of a Selective Survivin Suppressant YM155 and Alemtuzumab in Adult T-Cell Leukemia